A premarket regulatory submission demonstrating that a new medical device is substantially equivalent to a legally marketed predicate device, allowing it to be cleared for commercial distribution without full clinical trials.

What category does FDA 510(k) belong to in BCI?

FDA 510(k) is a Regulatory concept in brain-computer interface science.

FDA 510(k) — BCI Glossary

A 510(k) is a premarket submission made to the FDA to demonstrate that a new device is "substantially equivalent" to an already legally marketed device (the predicate). If the FDA concurs with the substantial equivalence determination, the device is "cleared" for marketing. The 510(k) pathway is faster and less expensive than the Premarket Approval (PMA) pathway, as it typically does not require clinical trial data — only bench testing, biocompatibility testing, and performance comparisons to the predicate device.

Process

Identify a predicate device: A legally marketed device with the same intended use and similar technological characteristics
Demonstrate substantial equivalence: Through bench testing, performance data, and sometimes limited clinical data, show that the new device is as safe and effective as the predicate
Submit the 510(k): A detailed dossier including device description, predicate comparison, performance testing, biocompatibility, and labeling
FDA review: Typically 90 days for a standard 510(k); may be longer with additional information requests

Relevance to BCI

The 510(k) pathway is relevant to non-invasive and lower-risk BCI components:

EEG systems: Clinical EEG recording systems (Natus, Compumedics) are typically 510(k) cleared using earlier EEG systems as predicates
Consumer EEG: Some consumer neurotechnology products seek 510(k) clearance when making medical claims
BCI software: Software that processes EEG signals for specific clinical purposes may require 510(k) clearance as a medical device software

Invasive BCI implants (Neuralink N1, Synchron Stentrode, Utah Array) are too novel and high-risk for the 510(k) pathway. These devices require IDE-authorized clinical studies followed by PMA submission, the most rigorous FDA pathway.

Limitations

The 510(k) pathway has been criticized for allowing devices to reach market based on equivalence to predicates rather than independent demonstration of safety and effectiveness. For BCI, this is largely a moot concern — the most clinically significant BCI devices (implanted neural interfaces) are classified as Class III devices requiring PMA, not 510(k) clearance.